Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 531 participants.

Also called NCT02648126

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 4
Enrolled
  • 531 participants (planned count) (from the registry)
Sponsor
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (from the registry)
Registry
  • NCT NCT02648126
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02648126. Allocation not applicable; no masking; primary purpose diagnostic. Start 2015-11 (registry gives no type); primary completion 2017-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa
Condition
Red-Cell Aplasia, Pure
Condition
Renal Insufficiency, Chronic
Intervention (Procedure)
Pure Red Cell Aplasia diagnostic confirmation
Lead sponsor
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (class: other)

Record details

Record id
cardio:ct-nct02648126
Content hash
684b5859d4109107d0819ea9501ab0d4bddc5347bcf10794cde60d22c024bf81